-
1 Comment
Pulike Biological Engineering, Inc is currently in a long term uptrend where the price is trading 5.0% above its 200 day moving average.
From a valuation standpoint, the stock is 28.4% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 6.9.
Pulike Biological Engineering, Inc's total revenue rose by 46.2% to $281M since the same quarter in the previous year.
Its net income has increased by 296.3% to $56M since the same quarter in the previous year.
Finally, its free cash flow grew by 81.3% to $82M since the same quarter in the previous year.
Based on the above factors, Pulike Biological Engineering, Inc gets an overall score of 5/5.
| Exchange | SHG |
|---|---|
| CurrencyCode | CNY |
| ISIN | CNE1000025N0 |
| Sector | Healthcare |
| Industry | Biotechnology |
| Beta | 0.43 |
|---|---|
| Market Cap | 4B |
| PE Ratio | 43.76 |
| Target Price | 14.65 |
| Dividend Yield | None |
Pulike Biological Engineering, Inc. engages in the research and development, production, and marketing of veterinary biological products and drugs. It offers vaccines, antibodies, and medicines for swine and poultry, as well as disinfectants. The company was founded in 1995 and is headquartered in Luoyang, China.
Learn MoreHere's how to backtest a trading strategy or backtest a portfolio for 603566.SHG using our backtest tool. PyInvesting provides the backtesting software for you to backtest your investment strategy. Our backtest software is written using Python code and allows you to backtest stock, backtest etf, backtest options, backtest crypto and backtest forex online. Our backtesting Python framework is highly robust and gives you a realistic simulation of how your strategy would have performed in the past using backtest data.
© PyInvesting 2025
